Jim Irsay, longtime Indianapolis Colts owner, dies at 65
Indianapolis Colts owner and CEO Jim Irsay has died at the age of 65, the team announced on Wednesday.
The Colts said Irsay died 'peacefully in his sleep' on Wednesday afternoon. No cause of death was given.
'Jim's dedication and passion for the Indianapolis Colts in addition to his generosity, commitment to the community, and most importantly, his love for his family were unsurpassed,' the team said in a statement.
Before becoming the owner of the franchise, Irsay was named general manager at 24 years old, the youngest in team history to ever hold that job, according to the Colts.
In 1995, he took a more prominent role within the team before becoming the sole owner in December 1997, after the death of his father, Robert Irsay.
During his time with the organization, the Colts won 10 division championships, made two Super Bowl appearances and oversaw the team winning their fourth title in 2006, when Indianapolis defeated the Chicago Bears in Super Bowl XLI.
'Jim will be deeply missed by his family, the Colts organization, and fans everywhere, but we remain inspired by his caring and unique spirit,' the team added.
Earlier on Wednesday, Irsay tweeted his support for the Indiana Pacers ahead of Game 1 of the Eastern Conference finals against the New York Knicks.
'Go PACERS. Good luck to Herb, the entire @Pacers organization, and our city!,' Irsay wrote.
NFL commissioner Roger Goodell called Irsay a 'friend' and a 'man deeply committed to his family, the game, the Colts, and the Indianapolis community.'
'He led with integrity, passion and care for the Colts' players, coaches and staff, and his courageous work in support of mental health will be a lasting legacy. Outside of football, he was a talented musician and built an extraordinary collection of historical and musical artifacts that he shared with people across the country,' Goodell added.
'On behalf of the entire NFL, I extend my heartfelt condolences to Jim's daughters and their families, and to his many friends throughout the NFL.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Washington Post
32 minutes ago
- Washington Post
Phillies place Bryce Harper on injured list with wrist inflammation
PITTSBURGH — The scuffling Philadelphia Phillies suffered a blow Saturday when they placed first baseman Bryce Harper on the 10-day injured list because of right wrist inflammation before their game against the Pirates. Harper sat out Friday night's 5-4 loss to the Pirates. The move is retroactive to Friday. The two-time National League MVP and eight-time All-Star is hitting .258 with nine home runs, 34 RBIs and eight stolen bases in 57 games. He missed five games from May 26 to June 2 with a bruised right elbow after being hit by a pitch from Atlanta's Spencer Strider.
Bloomberg
34 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
